30 results about "Phosphoproteomics" patented technology

The invention provides a method for identifying a human growth hormone protein existence form biomarker spectrum, which comprises the following steps: collecting human growth hormone secreting pituitary adenoma and normal pituitary tissue samples, respectively extracting tissue proteins, carrying out two-way gel electrophoresis, western blot and coomassie brilliant blue staining, scanning a visual PVDF membrane and a two-way gel into a digital image, digesting corresponding two-way gel protein spots with trypsin, purifying, and identifying a GHP biomarker spectrum through mass spectrum identification and bioinformatics analysis; and identifying post-translational modifications and shear variations on GHP by using quantitative phosphorylated proteomics, ubiquitinated proteomics, and acetylated proteomics analysis in combination with bioinformatics. According to the invention, the GHP change mode between the growth hormone secreting pituitary adenoma and normal pituitary tissues can be identified, 46 kinds of GHPs are identified in the growth hormone secreting pituitary adenoma, 35 kinds of GHPs are identified in the normal pituitary tissues, and 11 kinds of GHPs only appear in the growth hormone secreting pituitary adenoma tissues.

The invention discloses a preparation method, product and application of nano calcium phosphate used for polyphosphopeptide enrichment and phosphorylation site identification. The preparation method comprises the following steps: adding calcium salts in sequence in an alkaline solution The aqueous solution and the phosphate aqueous solution are stirred, and dried after the reaction to obtain nano calcium phosphate material. In the present invention, due to the strong interaction between calcium ions and phosphate radicals, nano-calcium phosphate can effectively achieve selective enrichment of polyphosphopeptides and identification of phosphorylation sites; at the same time, the calcium phosphate nanomaterials prepared by the method of the present invention are A biofunctional material with simple synthesis, low cost and high stability has broad application prospects in phosphorylation proteomics research.

Methods and reagents for labeling molecules of interest in a plurality of samples, and then combining and selecting labeled molecules away from unlabeled molecules for use in simultaneous co-assaying analysis. The reagents comprise labeling means of distinguishable radioactive isotopes which remain with the labeled molecules. Additionally, the reagents also comprise selection means which can be affinity tags, beads, or immobilized surface which may remain or be cleaved off through cleavable linkers. A set of labeling reagent can be used to label a plurality of samples, combine them before or after selecting / enriching for labeled molecules and co-assay together for reliable comparison. This invention has many applications in comparing and panning for differentially abundant molecules or differential modification of molecules for proteomics, glycomics, phospho-proteomics, metabolomics, epi-genomics . . . studies.

The invention discloses a mini protein reactor applied to preparation of a proteome sample and an application of the mini protein reactor and relates to the field of analytical chemistry. The mini protein reactor mainly comprises IMAC (immobilized metal chelating chromatography) magnetic beads and C18 beads. Smaller than 10 mu L of serum is expected to be taken as a sample for general situation analysis of proteome and can be used for translational research. According to the method, complicated sample preparation steps in proteomics are realized with a series column separation technology and include phosphoprotein pre-concentration, reduction, alkylation and digestion as well as desalination and fractionation. The method is easy to use, consumes short time (2 hours), is high in throughput,high in sensitivity (capable of detecting more than 100 phosphoprotein) and good in repeatability (R is larger than 0.99), is an effective method which can mine the most proteome data no matter fromthe number or from the variety and is speculated to be applied to technology translational research of non-labeled quantitative phosphoproteomics.

The state of protein phosphorylation and glycosylation can be key determinants of cellular physiology such as early stage cancer, but the development of phosphoproteins and / or glycoproteins in biofluids for disease diagnosis remains elusive. Here we demonstrate, for the first time, a strategy to isolate and identify phosphoproteins / glycoproteins in extracellular vesicles (EVs) from human plasma as potential markers to differentiate disease from healthy states. We identified close to 10,000 unique phosphopeptides in EVs by isolating from small volume of plasma samples. Using label-free quantitative phosphoproteomics, we identified 144 phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer than in healthy controls. Several novel biomarkers were validated in individual patients using Paralleled Reaction Monitoring for targeted quantitation. Similarly a group of glycoproteins in plasma EVs are identified. The study demonstrated that the development of phosphoproteins and / or glycoproteins in plasma EV as disease biomarkers is highly feasible and may transform cancer screening and monitoring.

The present invention relates to a rapid processing method for phosphorylated proteome samples. Utilizing the advantage that high-concentration trypsin can promote rapid enzymatic hydrolysis of proteins, a new type of sample processing method integrating cell lysis and proteolysis is developed, and its Applied to the analysis of phosphoproteomics. Thanks to the deep mechanism of simultaneous cell lysis and proteolysis promoted by the high concentration of trypsin, the cell sample can be rapidly converted into a peptide mixture in a single step. During the enrichment of phosphopeptides, non-phosphorylated peptides As well as various other mass spectrometrically incompatible impurities, can be removed. The present invention only needs 25 minutes to realize the rapid transition from cells to peptides, and in the normal control group, the simplest method also needs at least 16 hours; The excellent coverage of mass spectrum identification proves the accuracy and efficiency of this sample pretreatment method.

The invention relates to the preparation of a Ti(IV)-IMAC organic monolithic small column, which is used for phosphorylated proteomics analysis of trace biological samples. The organic monolithic column material is a polymethacrylate polymer with rich pore structure, high specific surface area, and many active sites for enriching titanium ions; at the same time, due to its hydrophilic material surface, Phosphopeptide enrichment showed a strong enrichment ability. It was used in the phosphoproteomics analysis of 5g HeLa cells, and more than 1000 non-redundant phosphorylation sites were identified on average, and the enrichment specificity was as high as 92.5%. More importantly, the preparation of the Ti(IV)-IMAC organic monolithic column is simple. Compared with the packed column, it can be prepared by light-induced free radical polymerization in only a few minutes; and there is no need to prepare a stopper, The preparation time of the enrichment material is reduced to a large extent.

The invention relates to a method for accumulating cotton phosphorylated protein, belonging to the field of biotechnology. The method comprises the steps of extracting cotton total protein and utilizing the Al(OH)3 affinity chromatography to accumulate cotton phosphorylated protein. By using the method, 12mu g of phosphorylated protein can be accumulated from 1mg of cotton total protein so that the accumulation efficiency is more than 6 times of that of the imported Qiagen kit. The two-dimensional electrophoresis technology and the phosphorylated protein specific dye ProQ DiamondTM (Invitrogen) dyeing test prove that the phosphorylated protein accumulated by the method has no non-phosphorylated protein. The method can replace the expensive imported kit, be used to accumulate phosphorylated protein efficiently and specifically and be widely used in researches such as phosphorylated proteomics and cellular signal.

The invention relates to a separation and purification technique, in particular to an affinity chromatography stationary phase of immobilized metal and a preparation method thereof. The structure of the stationary phase is shown in the drawing; wherein, the grain diameter of GMAPolymer micro-sphere is 10nm-50[mu]m; the GMAPolymer micro-sphere is poly-methacrylic acid glycidyl esters micro-sphere. By carrying out amination and phosphoric esterification, a synthesis method of the high-performance poly-methacrylic acid glycidyl ester-group novel affinity chromatography stationary phase is gained and used for the research in phosphorylation proteomics and highly-selective separation, enrichment and purification of phosphopeptide by the chelation with zirconium ions and iron ions; meanwhile, compared with the traditional stationary phase, the affinity chromatography stationary phase reduces the nonspecific adsorption on the non-phosphopeptide.

Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is TRPV4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues. TRPV4 was also found to be elevated mostly in invasive breast cancer cell lines and less so in non-invasive breast cancer cell lines. These data led us to hypothesize that TRPV4 confer early traits of metastatic cancer cells. Functional studies revealed that silencing of TRPV4 expression diminished breast cancer cell migration and invasion significantly but not proliferation. Silencing expression of TRPV4 in metastatic breast cancer cells also reduced the number and size of metastatic colonies in mice. This supports the notion that TRPV4 is an attractive drug target to curb metastasis. Further experimentations suggested that the functional effect of TRPV4 on breast cancer cellular processes was associated with regulation of intracellular Ca2+, cell plasticity and expression of cell-cell adhesion proteins such as beta-catenin and E-cadherin. The latter two events have obvious implications in cancer invasion and intravasation / extravasation. We have also made novel observations that activation of TRPV4 by PDD led to activation of AKT and FAK pathways, both shown to be important to cell migration. In particular, downregulation of E-cadherin and b-catenin following TRPV4 activation has been shown to be mediated by the AKT pathway. Collectively, our data suggest that activation of Ca2+ dependent cascades and pathways associated with cell migration mediate TRPV4 function in breast cancer metastasis.